Royalty Net Income vs Depreciation Analysis

RPRX Stock

USD 25.54 0.14 0.55%

Royalty Pharma financial indicator trend analysis is much more than just breaking down Royalty Pharma Plc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Royalty Pharma Plc is a good investment. Please check the relationship between Royalty Pharma Net Income and its Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Net Income vs Depreciation

Net Income vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Royalty Pharma Plc Net Income account and Depreciation. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Royalty Pharma's Net Income and Depreciation is 0.82. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Depreciation in the same time period over historical financial statements of Royalty Pharma Plc, assuming nothing else is changed. The correlation between historical values of Royalty Pharma's Net Income and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Royalty Pharma Plc are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Net Income i.e., Royalty Pharma's Net Income and Depreciation go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Royalty Pharma Plc financial statement analysis. It represents the amount of money remaining after all of Royalty Pharma Plc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Depreciation

Depreciation indicates how much of Royalty Pharma Plc value has been used up. For tax purposes Royalty Pharma can deduct the cost of the tangible assets it purchases as business expenses. However, Royalty Pharma Plc must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Royalty Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Royalty Pharma Plc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Royalty Pharma's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is expected to grow at the current pace this year, whereas Sales General And Administrative To Revenue is likely to drop 0.06 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	23.0M	5.7M	395.1M	414.9M
Interest Income	53.5M	78.3M	72.3M	45.0M

Depreciation And Amortization Interest Income

Royalty Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Short Long Term Debt Total	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments
Total Assets		0.78	0.59	0.98	-0.33	0.8	0.67	0.54	0.53	0.32	0.39	0.39	0.95	-0.24	0.21	-0.36	-0.17	0.93	0.92	0.88	0.35	0.7	0.86	0.41	0.13	-0.44
Other Current Liab	0.78		0.62	0.76	-0.24	0.42	0.87	0.19	0.23	0.29	0.16	0.25	0.81	-0.27	0.42	-0.3	0.13	0.7	0.6	0.93	0.16	0.15	0.42	0.16	0.03	-0.06
Total Current Liabilities	0.59	0.62		0.53	-0.17	0.26	0.81	0.27	0.18	0.27	0.1	0.83	0.7	-0.25	0.42	-0.25	0.13	0.65	0.56	0.72	-0.01	0.27	0.36	-0.1	-0.19	0.04
Total Stockholder Equity	0.98	0.76	0.53		-0.32	0.83	0.59	0.45	0.48	0.29	0.53	0.29	0.91	-0.25	0.26	-0.35	-0.13	0.91	0.91	0.82	0.23	0.67	0.81	0.4	0.01	-0.51
Other Liab	-0.33	-0.24	-0.17	-0.32		-0.3	-0.2	-0.71	-0.27	-0.29	-0.09	-0.08	-0.33	-0.71	-0.1	0.98	-0.2	-0.33	-0.32	-0.26	-0.08	-0.27	-0.29	-0.25	-0.05	0.25
Accounts Payable	0.8	0.42	0.26	0.83	-0.3		0.18	0.62	0.68	-0.18	0.38	0.17	0.71	-0.23	0.06	-0.25	-0.32	0.74	0.79	0.45	0.07	0.83	0.83	0.78	0.05	-0.87
Cash	0.67	0.87	0.81	0.59	-0.2	0.18		0.23	0.14	0.46	0.0	0.47	0.79	-0.27	0.51	-0.29	0.19	0.7	0.58	0.93	0.32	0.15	0.33	-0.12	0.13	0.2
Other Assets	0.54	0.19	0.27	0.45	-0.71	0.62	0.23		0.63	0.03	-0.16	0.3	0.55	0.28	-0.03	-0.66	-0.19	0.56	0.57	0.34	0.41	0.75	0.69	0.64	0.45	-0.52
Common Stock Shares Outstanding	0.53	0.23	0.18	0.48	-0.27	0.68	0.14	0.63		-0.2	-0.12	0.25	0.46	-0.07	-0.22	-0.18	-0.39	0.59	0.58	0.27	0.12	0.6	0.74	0.72	0.07	-0.57
Short Term Investments	0.32	0.29	0.27	0.29	-0.29	-0.18	0.46	0.03	-0.2		0.32	0.24	0.27	0.35	-0.01	-0.39	0.09	0.27	0.27	0.49	0.54	0.0	0.22	-0.56	0.13	0.52
Inventory	0.39	0.16	0.1	0.53	-0.09	0.38	0.0	-0.16	-0.12	0.32		-0.09	0.29	-0.08	0.3	-0.14	0.11	0.37	0.47	0.19	-0.21	0.28	0.22	-0.17	-0.52	-0.32
Other Current Assets	0.39	0.25	0.83	0.29	-0.08	0.17	0.47	0.3	0.25	0.24	-0.09		0.39	-0.01	-0.12	-0.12	-0.16	0.37	0.32	0.43	0.05	0.26	0.43	-0.07	-0.1	0.12
Total Liab	0.95	0.81	0.7	0.91	-0.33	0.71	0.79	0.55	0.46	0.27	0.29	0.39		-0.34	0.46	-0.37	-0.03	0.96	0.92	0.91	0.34	0.67	0.73	0.34	0.16	-0.39
Treasury Stock	-0.24	-0.27	-0.25	-0.25	-0.71	-0.23	-0.27	0.28	-0.07	0.35	-0.08	-0.01	-0.34		-0.42	-0.68	0.09	-0.32	-0.3	-0.26	0.01	-0.2	-0.08	-0.11	0.0	0.2
Common Stock	0.21	0.42	0.42	0.26	-0.1	0.06	0.51	-0.03	-0.22	-0.01	0.3	-0.12	0.46	-0.42		-0.18	0.53	0.42	0.37	0.37	-0.18	0.07	-0.21	-0.19	-0.22	-0.12
Property Plant Equipment	-0.36	-0.3	-0.25	-0.35	0.98	-0.25	-0.29	-0.66	-0.18	-0.39	-0.14	-0.12	-0.37	-0.68	-0.18		-0.3	-0.36	-0.35	-0.33	-0.11	-0.26	-0.28	-0.14	-0.04	0.17
Intangible Assets	-0.17	0.13	0.13	-0.13	-0.2	-0.32	0.19	-0.19	-0.39	0.09	0.11	-0.16	-0.03	0.09	0.53	-0.3		-0.07	-0.12	0.03	-0.28	-0.34	-0.45	-0.37	-0.27	0.21
Net Tangible Assets	0.93	0.7	0.65	0.91	-0.33	0.74	0.7	0.56	0.59	0.27	0.37	0.37	0.96	-0.32	0.42	-0.36	-0.07		0.98	0.83	0.3	0.74	0.78	0.34	0.05	-0.46
Retained Earnings	0.92	0.6	0.56	0.91	-0.32	0.79	0.58	0.57	0.58	0.27	0.47	0.32	0.92	-0.3	0.37	-0.35	-0.12	0.98		0.75	0.31	0.81	0.82	0.36	0.04	-0.54
Total Current Assets	0.88	0.93	0.72	0.82	-0.26	0.45	0.93	0.34	0.27	0.49	0.19	0.43	0.91	-0.26	0.37	-0.33	0.03	0.83	0.75		0.41	0.37	0.59	0.09	0.19	-0.03
Short Long Term Debt Total	0.35	0.16	-0.01	0.23	-0.08	0.07	0.32	0.41	0.12	0.54	-0.21	0.05	0.34	0.01	-0.18	-0.11	-0.28	0.3	0.31	0.41		0.39	0.46	0.04	0.86	0.19
Net Debt	0.7	0.15	0.27	0.67	-0.27	0.83	0.15	0.75	0.6	0.0	0.28	0.26	0.67	-0.2	0.07	-0.26	-0.34	0.74	0.81	0.37	0.39		0.84	0.6	0.3	-0.73
Non Current Assets Total	0.86	0.42	0.36	0.81	-0.29	0.83	0.33	0.69	0.74	0.22	0.22	0.43	0.73	-0.08	-0.21	-0.28	-0.45	0.78	0.82	0.59	0.46	0.84		0.58	0.28	-0.53
Non Currrent Assets Other	0.41	0.16	-0.1	0.4	-0.25	0.78	-0.12	0.64	0.72	-0.56	-0.17	-0.07	0.34	-0.11	-0.19	-0.14	-0.37	0.34	0.36	0.09	0.04	0.6	0.58		0.29	-0.82
Long Term Debt	0.13	0.03	-0.19	0.01	-0.05	0.05	0.13	0.45	0.07	0.13	-0.52	-0.1	0.16	0.0	-0.22	-0.04	-0.27	0.05	0.04	0.19	0.86	0.3	0.28	0.29		0.05
Cash And Short Term Investments	-0.44	-0.06	0.04	-0.51	0.25	-0.87	0.2	-0.52	-0.57	0.52	-0.32	0.12	-0.39	0.2	-0.12	0.17	0.21	-0.46	-0.54	-0.03	0.19	-0.73	-0.53	-0.82	0.05

Click cells to compare fundamentals

Royalty Pharma Account Relationship Matchups

Royalty Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.4B	21.1B	17.5B	16.8B	16.4B	17.2B
Other Current Liab	9.2M	297.1M	165.6M	161.4M	146.2M	153.5M
Total Current Liabilities	333.4M	307.9M	171.3M	1.2B	161.4M	132.4M
Total Stockholder Equity	6.1B	9.9B	5.8B	5.6B	6.5B	6.9B
Accounts Payable	11.2M	10.8M	5.6M	7.9M	15.2M	15.9M
Cash	283.7M	1.0B	1.5B	1.7B	477.0M	343.9M
Other Assets	10.9B	5.1B	13.7B	13.5B	15.5B	16.3B
Common Stock Shares Outstanding	365.9M	375.5M	414.8M	438.0M	602.9M	409.1M
Short Term Investments	509.5M	983M	1.3B	717.0M	18.3M	17.4M
Other Current Assets	92K	8.6M	6.6M	90.5M	3.8M	5.8M
Total Liab	6.3B	6.1B	7.3B	7.3B	6.3B	6.6B
Intangible Assets	51.7M	28.7M	5.7M	14.5M	1.8M	1.7M
Net Tangible Assets	6.1B	4.8B	5.8B	5.6B	6.5B	3.7B
Retained Earnings	2.8B	1.9B	2.3B	2.0B	2.5B	1.4B
Total Current Assets	832.1M	2.7B	2.9B	2.6B	1.3B	1.6B
Short Long Term Debt Total	6.2B	6.1B	14.0B	7.1B	6.1B	8.5B
Net Debt	6.0B	4.8B	5.6B	5.4B	5.7B	5.9B
Non Current Assets Total	11.6B	13.3B	14.6B	14.3B	15.1B	14.2B
Non Currrent Assets Other	88.0M	28.6M	4.1M	15.1M	14.1B	14.8B
Long Term Debt	6.0B	5.8B	7.1B	6.1B	6.1B	6.8B
Cash And Short Term Investments	793.2M	2.0B	2.8B	2.4B	495.3M	470.5M
Net Receivables	38.8M	39.2M	68.3M	727.9M	775.1M	813.8M
Long Term Debt Total	6.0B	5.8B	7.1B	6.1B	7.0B	6.9B
Liabilities And Stockholders Equity	12.4B	21.1B	17.5B	16.8B	16.4B	17.5B
Non Current Liabilities Total	6.0B	5.8B	7.1B	6.1B	6.1B	6.9B
Other Stockholder Equity	(4.3M)	7.9B	3.5B	3.7B	4.0B	3.5B
Net Invested Capital	12.3B	10.6B	12.9B	12.7B	12.7B	13.2B
Long Term Investments	11.5B	13.0B	14.4B	14.1B	15.1B	14.1B
Accumulated Other Comprehensive Income	2.1M	34.4M	16.5M	63K	72.5K	68.8K
Net Working Capital	498.7M	2.4B	2.7B	1.4B	1.1B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Net Income vs Depreciation Analysis

Net Income vs Depreciation

Net Income vs Depreciation Correlation Analysis

Correlation Coefficient

Net Income

Depreciation

Royalty Pharma fundamental ratios Correlations

Royalty Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Royalty Pharma fundamental ratios Accounts

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Property Plant Equipment	+ 0.98	Other Liab
Retained Earnings	+ 0.98	Net Tangible Assets
Net Tangible Assets	+ 0.96	Total Liab
Total Liab	+ 0.95	Total Assets
Net Tangible Assets	+ 0.93	Total Assets

Cash And Short Term Investments	- 0.87	Accounts Payable
Cash And Short Term Investments	- 0.82	Non Currrent Assets Other
Cash And Short Term Investments	- 0.73	Net Debt
Treasury Stock	- 0.71	Other Liab
Other Assets	- 0.71	Other Liab
Property Plant Equipment	- 0.68	Treasury Stock